皓元醫藥(688131.SH)2021年度淨利潤預增40%-55%
格隆匯1月24日丨皓元醫藥(688131.SH)公佈,預計2021年年度實現營業收入為9.53億元到9.84億元,與上年同期相比,將增加3.18億元到3.49億元,同比增長50%到55%。
預計2021年年度實現歸屬於母公司所有者的淨利潤為1.798億元到1.991億元,與上年同期相比,將增加5137.33萬元到7063.83萬元,同比增長40%到55%。
預計2021年年度實現扣除非經常性損益後歸屬母公司所有者的淨利潤為1.66億元到1.84億元,與上年同期相比,將增加4745萬元到6524.37萬元,同比增長40%到55%。
業績變化的主要原因如下:1、公司所處CRO、CDMO行業需求旺盛,對公司的服務能力、供給能力提出了新的要求,也促進了公司業務在報吿期內實現快速發展。公司持續關注產品、服務質量,品牌知名度持續提高,有利促進了市場的開拓。報吿期內,基於前述原因公司的訂單大幅增加,帶動了銷售收入增加。
2、報吿期內,公司加快人才隊伍建設,加大上海總部、安徽省馬鞍山市的技術平台建設,研發投入有所增加。
3、公司加速擴大工具化合物、分子砌塊可供給的產品線,研發市場的服務能力得到快速擴大,但相應費用支出有所增長。
綜上,雖然公司在人員和產業佈局上的快速擴張增加了當期成本費用,對短期的業績有一定壓力,但有利於積蓄公司發展潛力,有利於公司的長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.